Immunome Inc.
Organization details
- Legal name
- Immunome Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Bothell
- Headquarters state / province
- Washington
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- IMNM
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001472012
- EIN
- 77-0694340
Board of directors
-
Carol Schafer · DirectorSince 2024
-
Clay B. Siegall · Director · President and CEOSince 2023
-
Franklyn G. Prendergast · DirectorSince 2023
-
Isaac Barchas · DirectorSince 2023
-
James P. Boylan · DirectorSince 2023
- Since 2023
-
John L. Lamattina · DirectorSince 2023
-
Michael Lefenfeld · DirectorSince 2023
-
Michael Rapp · DirectorSince 2023
-
Philip Wagenheim · DirectorSince 2023
-
Purnanand D. Sarma · Director · President and CEOSince 2023
-
Richard A. Baron · DirectorSince 2023
-
Sandra M. Swain · DirectorSince 2024
Chief executives
Director election results
Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
76.0%
-
99.8%
-
99.8%
Board connections
6 of this board's directors also sit on 12 other boards. 11 are in the same sector.
-
Ascendis Pharma A/S Same sectorvia Jean Jacques Bienaime
-
BioMarin Pharmaceutical Inc. Same sectorvia Jean Jacques Bienaime
-
CAMP4 Therapeutics Corporation Same sectorvia James P. Boylan
-
Compass Therapeutics Inc. Same sectorvia James P. Boylan
-
Incyte Corp. Same sectorvia Jean Jacques Bienaime
-
Insmed Incorporated Same sectorvia Carol Schafer
-
Keros Therapeutics Inc. Same sectorvia Jean Jacques Bienaime
-
Kura Oncology Inc. Same sectorvia Carol Schafer
-
Ligand Pharmaceuticals Incorporated Same sectorvia John L. Lamattina
-
Shattuck Labs Inc. Same sectorvia Clay B. Siegall
- via Philip Wagenheim
-
Zenas BioPharma Inc. Same sectorvia James P. Boylan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $2,305,990
- 11 purchases by 3 insiders
- Sold, last 12 months
- $27,508,461
- 28 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 11, 2026 | Higgins Jack Officer (Chief Scientific Officer) | Option exercise | +18,000 | $1.35 | $24,300 |
| Sep 11, 2026 | Higgins Jack Officer (Chief Scientific Officer) | Open-market sale | −13,200 | $25.32 | $334,224 |
| Sep 11, 2026 | Higgins Jack Officer (Chief Scientific Officer) | Gift | −8,800 | — | — |
| Aug 12, 2026 | Isaac Barchas Director | Open-market sale | −11,048 | $27.25 | $301,058 |
| Aug 11, 2026 | Isaac Barchas Director | Open-market sale | −62,291 | $26.23 | $1,633,893 |
| Aug 10, 2026 | Isaac Barchas Director | Open-market sale | −10,125 | $26.07 | $263,959 |
| Aug 7, 2026 | Isaac Barchas Director | Open-market sale | −15,248 | $26.06 | $397,363 |
| Aug 6, 2026 | Isaac Barchas Director | Open-market sale | −20,840 | $26.06 | $543,090 |
| Aug 4, 2026 | Horn Kinney Officer (CHIEF BUSINESS OFFICER) | Option exercise | +50,366 | $12.92 | $650,729 |
| Aug 4, 2026 | Horn Kinney Officer (CHIEF BUSINESS OFFICER) | Option exercise | +40,250 | $10.60 | $426,650 |
| Aug 4, 2026 | Horn Kinney Officer (CHIEF BUSINESS OFFICER) | Open-market sale | −90,616 | $25.09 | $2,273,555 |
| Jul 23, 2026 | Higgins Jack Officer (Chief Scientific Officer) | Grant or award | +38,250 | — | — |
| Jul 23, 2026 | Horn Kinney Officer (CHIEF BUSINESS OFFICER) | Grant or award | +31,250 | — | — |
| Jul 23, 2026 | Clay B. Siegall Director, Officer (President and CEO) | Grant or award | +180,000 | — | — |
| Jul 23, 2026 | Stoneman Sandra G. Officer (CHIEF LEGAL OFFICER & GC) | Grant or award | +38,250 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Immunome Inc.
Who is the CEO of Immunome Inc.?
Clay B. Siegall has been Immunome Inc.'s President and CEO since October 2023.
How many directors are on Immunome Inc.'s board?
Immunome Inc.'s board has 13 directors: Carol Schafer, Clay B. Siegall, Franklyn G. Prendergast, Isaac Barchas, James P. Boylan, Jean Jacques Bienaime, John L. Lamattina, Michael Lefenfeld, Michael Rapp, Philip Wagenheim and 3 others.
Are Immunome Inc. insiders buying or selling shares?
Over the last 12 months, Immunome Inc. insiders bought $2.3 million of shares in 11 purchases and sold $27.5 million of shares in 28 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="immunome-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.